Ziprasidone
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
First Episode Psychosis
Conditions
First Episode Psychosis
Trial Timeline
— → May 1, 2010
NCT ID
NCT01157559About Ziprasidone
Ziprasidone is a approved stage product being developed by Pfizer for First Episode Psychosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01157559. Target conditions include First Episode Psychosis.
What happened to similar drugs?
2 of 6 similar drugs in First Episode Psychosis were approved
Approved (2) Terminated (1) Active (4)
🔄HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabineJiangsu Hengrui MedicinePhase 3
🔄Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabineJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01157559 | Approved | Completed |
| NCT02935998 | Approved | UNKNOWN |
| NCT01293825 | Approved | Completed |
| NCT01198353 | Approved | Completed |
| NCT00579670 | Pre-clinical | Completed |
| NCT00454883 | Pre-clinical | Completed |
| NCT00406315 | Approved | Completed |
| NCT00421954 | Phase 3 | Completed |
| NCT01053429 | Pre-clinical | Completed |
| NCT00458211 | Approved | Completed |
| NCT00237666 | Approved | Completed |
| NCT00351000 | Approved | Completed |
| NCT00137020 | Approved | Completed |
| NCT00645229 | Phase 3 | Terminated |
| NCT00649064 | Approved | Completed |
| NCT00650429 | Approved | Completed |
| NCT00395031 | Phase 2/3 | Completed |
| NCT00645320 | Approved | Completed |
| NCT00644800 | Approved | Completed |
| NCT00143351 | Phase 3 | Completed |
Competing Products
12 competing products in First Episode Psychosis